Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer
To develop a strategy to improve response to bacillus Calmette-Gueri (BCG) using cytokine gene therapy ( + ). MB49-PSA tumor-bearing C57BL/6N mice were assigned into four groups: control; + therapy; BCG therapy or combined therapy ( + and BCG). In schedule 1, cytokine gene therapy was delivered befo...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2020-06, Vol.16 (17), p.1179-1188 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1188 |
|---|---|
| container_issue | 17 |
| container_start_page | 1179 |
| container_title | Future oncology (London, England) |
| container_volume | 16 |
| creator | Tham, Sin Mun Mahendran, Ratha Chiong, Edmund Wu, Qing Hui Esuvaranathan, Kesavan |
| description | To develop a strategy to improve response to bacillus Calmette-Gueri (BCG) using cytokine gene therapy (
+
).
MB49-PSA tumor-bearing C57BL/6N mice were assigned into four groups: control;
+
therapy; BCG therapy or combined therapy (
+
and BCG). In schedule 1, cytokine gene therapy was delivered before BCG therapy (eight instillations). In schedule 2, cytokine gene and BCG therapy were instilled alternatively (eight instillations). Tumors were analyzed by immunohistochemistry and mRNA analysis and urinary immune cells by flow cytometry.
Combined therapy in schedule 2 reduced tumor growth, increased immune cell recruitment and was associated with reduced inflammation when compared with BCG therapy.
Alternating cytokine gene delivery with BCG therapy modulates the tumor environment increasing receptivity to BCG. |
| doi_str_mv | 10.2217/fon-2020-0137 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2396859376</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473448370</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-d4d969eb88bf12822897a48e8939ce613bdbfb5c960ad00d9d0233799cc15ec03</originalsourceid><addsrcrecordid>eNpdkbtOxDAQRS0E4l3SIks0NAG_EtslrGBBQqKB2nLsCSwk9mJvkPgsfoRvwtECBdWMZs5cXc1F6IiSM8aoPO9iqBhhpCKUyw20S6UQleKEbpZeSF01jRY7aC_nF0KE5DXZRjuc8ZpSpnfR63xwucM2eHzbha9P_AQB8OoZkl1-4MWwTPEd8jTACfIyhly2EV_O5mU5jCH-oQFbPIxpUc6H6KHHscNtb72HhJ0NDtIB2upsn-Hwp-6jx-urh9lNdXc_v51d3FWON2RVeeF1o6FVqu0oU4wpLa1QoDTXDhrKW992be10Q6wnxGtPGOdSa-doDY7wfXS61i3m30bIKzMssoO-twHimA3julG15rIp6Mk_9CWOKRR3hpVnCaG4nASrNeVSzDlBZ5ZpMdj0YSgxUwqmpGCmFMyUQuGPf1THdgD_R_--nX8DtmmC5w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473448370</pqid></control><display><type>article</type><title>Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer</title><source>MEDLINE</source><source>PubMed Central</source><creator>Tham, Sin Mun ; Mahendran, Ratha ; Chiong, Edmund ; Wu, Qing Hui ; Esuvaranathan, Kesavan</creator><creatorcontrib>Tham, Sin Mun ; Mahendran, Ratha ; Chiong, Edmund ; Wu, Qing Hui ; Esuvaranathan, Kesavan</creatorcontrib><description>To develop a strategy to improve response to bacillus Calmette-Gueri (BCG) using cytokine gene therapy (
+
).
MB49-PSA tumor-bearing C57BL/6N mice were assigned into four groups: control;
+
therapy; BCG therapy or combined therapy (
+
and BCG). In schedule 1, cytokine gene therapy was delivered before BCG therapy (eight instillations). In schedule 2, cytokine gene and BCG therapy were instilled alternatively (eight instillations). Tumors were analyzed by immunohistochemistry and mRNA analysis and urinary immune cells by flow cytometry.
Combined therapy in schedule 2 reduced tumor growth, increased immune cell recruitment and was associated with reduced inflammation when compared with BCG therapy.
Alternating cytokine gene delivery with BCG therapy modulates the tumor environment increasing receptivity to BCG.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2020-0137</identifier><identifier>PMID: 32351129</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Animals ; Antigens ; BCG Vaccine - therapeutic use ; Biomarkers ; Bladder cancer ; Combined Modality Therapy ; Cytokines ; Cytokines - genetics ; Disease Models, Animal ; Female ; Flow cytometry ; Gene Expression ; Gene therapy ; Genetic Therapy - methods ; Granulocyte-Macrophage Colony-Stimulating Factor - genetics ; Histology ; Immunomodulation - genetics ; Immunotherapy ; Interferon-alpha - genetics ; Mice ; Plasmids ; Prostate ; Schedules ; T-Lymphocytes - immunology ; T-Lymphocytes - metabolism ; Transfection ; Tumors ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - genetics ; Urinary Bladder Neoplasms - immunology ; Urinary Bladder Neoplasms - therapy ; Variance analysis ; Xenograft Model Antitumor Assays</subject><ispartof>Future oncology (London, England), 2020-06, Vol.16 (17), p.1179-1188</ispartof><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-d4d969eb88bf12822897a48e8939ce613bdbfb5c960ad00d9d0233799cc15ec03</citedby><cites>FETCH-LOGICAL-c360t-d4d969eb88bf12822897a48e8939ce613bdbfb5c960ad00d9d0233799cc15ec03</cites><orcidid>0000-0002-4359-2160</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32351129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tham, Sin Mun</creatorcontrib><creatorcontrib>Mahendran, Ratha</creatorcontrib><creatorcontrib>Chiong, Edmund</creatorcontrib><creatorcontrib>Wu, Qing Hui</creatorcontrib><creatorcontrib>Esuvaranathan, Kesavan</creatorcontrib><title>Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>To develop a strategy to improve response to bacillus Calmette-Gueri (BCG) using cytokine gene therapy (
+
).
MB49-PSA tumor-bearing C57BL/6N mice were assigned into four groups: control;
+
therapy; BCG therapy or combined therapy (
+
and BCG). In schedule 1, cytokine gene therapy was delivered before BCG therapy (eight instillations). In schedule 2, cytokine gene and BCG therapy were instilled alternatively (eight instillations). Tumors were analyzed by immunohistochemistry and mRNA analysis and urinary immune cells by flow cytometry.
Combined therapy in schedule 2 reduced tumor growth, increased immune cell recruitment and was associated with reduced inflammation when compared with BCG therapy.
Alternating cytokine gene delivery with BCG therapy modulates the tumor environment increasing receptivity to BCG.</description><subject>Animals</subject><subject>Antigens</subject><subject>BCG Vaccine - therapeutic use</subject><subject>Biomarkers</subject><subject>Bladder cancer</subject><subject>Combined Modality Therapy</subject><subject>Cytokines</subject><subject>Cytokines - genetics</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Flow cytometry</subject><subject>Gene Expression</subject><subject>Gene therapy</subject><subject>Genetic Therapy - methods</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - genetics</subject><subject>Histology</subject><subject>Immunomodulation - genetics</subject><subject>Immunotherapy</subject><subject>Interferon-alpha - genetics</subject><subject>Mice</subject><subject>Plasmids</subject><subject>Prostate</subject><subject>Schedules</subject><subject>T-Lymphocytes - immunology</subject><subject>T-Lymphocytes - metabolism</subject><subject>Transfection</subject><subject>Tumors</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - genetics</subject><subject>Urinary Bladder Neoplasms - immunology</subject><subject>Urinary Bladder Neoplasms - therapy</subject><subject>Variance analysis</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkbtOxDAQRS0E4l3SIks0NAG_EtslrGBBQqKB2nLsCSwk9mJvkPgsfoRvwtECBdWMZs5cXc1F6IiSM8aoPO9iqBhhpCKUyw20S6UQleKEbpZeSF01jRY7aC_nF0KE5DXZRjuc8ZpSpnfR63xwucM2eHzbha9P_AQB8OoZkl1-4MWwTPEd8jTACfIyhly2EV_O5mU5jCH-oQFbPIxpUc6H6KHHscNtb72HhJ0NDtIB2upsn-Hwp-6jx-urh9lNdXc_v51d3FWON2RVeeF1o6FVqu0oU4wpLa1QoDTXDhrKW992be10Q6wnxGtPGOdSa-doDY7wfXS61i3m30bIKzMssoO-twHimA3julG15rIp6Mk_9CWOKRR3hpVnCaG4nASrNeVSzDlBZ5ZpMdj0YSgxUwqmpGCmFMyUQuGPf1THdgD_R_--nX8DtmmC5w</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Tham, Sin Mun</creator><creator>Mahendran, Ratha</creator><creator>Chiong, Edmund</creator><creator>Wu, Qing Hui</creator><creator>Esuvaranathan, Kesavan</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4359-2160</orcidid></search><sort><creationdate>202006</creationdate><title>Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer</title><author>Tham, Sin Mun ; Mahendran, Ratha ; Chiong, Edmund ; Wu, Qing Hui ; Esuvaranathan, Kesavan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-d4d969eb88bf12822897a48e8939ce613bdbfb5c960ad00d9d0233799cc15ec03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antigens</topic><topic>BCG Vaccine - therapeutic use</topic><topic>Biomarkers</topic><topic>Bladder cancer</topic><topic>Combined Modality Therapy</topic><topic>Cytokines</topic><topic>Cytokines - genetics</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Flow cytometry</topic><topic>Gene Expression</topic><topic>Gene therapy</topic><topic>Genetic Therapy - methods</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - genetics</topic><topic>Histology</topic><topic>Immunomodulation - genetics</topic><topic>Immunotherapy</topic><topic>Interferon-alpha - genetics</topic><topic>Mice</topic><topic>Plasmids</topic><topic>Prostate</topic><topic>Schedules</topic><topic>T-Lymphocytes - immunology</topic><topic>T-Lymphocytes - metabolism</topic><topic>Transfection</topic><topic>Tumors</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - genetics</topic><topic>Urinary Bladder Neoplasms - immunology</topic><topic>Urinary Bladder Neoplasms - therapy</topic><topic>Variance analysis</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tham, Sin Mun</creatorcontrib><creatorcontrib>Mahendran, Ratha</creatorcontrib><creatorcontrib>Chiong, Edmund</creatorcontrib><creatorcontrib>Wu, Qing Hui</creatorcontrib><creatorcontrib>Esuvaranathan, Kesavan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tham, Sin Mun</au><au>Mahendran, Ratha</au><au>Chiong, Edmund</au><au>Wu, Qing Hui</au><au>Esuvaranathan, Kesavan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2020-06</date><risdate>2020</risdate><volume>16</volume><issue>17</issue><spage>1179</spage><epage>1188</epage><pages>1179-1188</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>To develop a strategy to improve response to bacillus Calmette-Gueri (BCG) using cytokine gene therapy (
+
).
MB49-PSA tumor-bearing C57BL/6N mice were assigned into four groups: control;
+
therapy; BCG therapy or combined therapy (
+
and BCG). In schedule 1, cytokine gene therapy was delivered before BCG therapy (eight instillations). In schedule 2, cytokine gene and BCG therapy were instilled alternatively (eight instillations). Tumors were analyzed by immunohistochemistry and mRNA analysis and urinary immune cells by flow cytometry.
Combined therapy in schedule 2 reduced tumor growth, increased immune cell recruitment and was associated with reduced inflammation when compared with BCG therapy.
Alternating cytokine gene delivery with BCG therapy modulates the tumor environment increasing receptivity to BCG.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>32351129</pmid><doi>10.2217/fon-2020-0137</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4359-2160</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2020-06, Vol.16 (17), p.1179-1188 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2396859376 |
| source | MEDLINE; PubMed Central |
| subjects | Animals Antigens BCG Vaccine - therapeutic use Biomarkers Bladder cancer Combined Modality Therapy Cytokines Cytokines - genetics Disease Models, Animal Female Flow cytometry Gene Expression Gene therapy Genetic Therapy - methods Granulocyte-Macrophage Colony-Stimulating Factor - genetics Histology Immunomodulation - genetics Immunotherapy Interferon-alpha - genetics Mice Plasmids Prostate Schedules T-Lymphocytes - immunology T-Lymphocytes - metabolism Transfection Tumors Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - immunology Urinary Bladder Neoplasms - therapy Variance analysis Xenograft Model Antitumor Assays |
| title | Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T10%3A35%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gmcsf%20and%20Ifn%CE%B1%20gene%20therapy%20improves%20the%20response%20to%20BCG%20immunotherapy%20in%20a%20murine%20model%20of%20bladder%20cancer&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Tham,%20Sin%20Mun&rft.date=2020-06&rft.volume=16&rft.issue=17&rft.spage=1179&rft.epage=1188&rft.pages=1179-1188&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2020-0137&rft_dat=%3Cproquest_cross%3E2473448370%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473448370&rft_id=info:pmid/32351129&rfr_iscdi=true |